Stage and histology are well-established prognostic factors for cervical cancer, but the importance of age has been controversial and a clear role for this factor has not yet been defined. We hypothesize that age will have a significant prognostic role. We aim to evaluate the significance of age as an independent prognostic factor in women with cervical cancer and evaluate the therapeutic consequences and survival outcomes as they relate to this factor. Surveillance, Epidemiology, and End Results (SEER) database was used to retrospectively analyze patients diagnosed with cervical cancer from 1973 to 2013 in the United States. Statistical analysis performed included the Log-Rank test, Chi-squared analysis, and the Cox Proportional Hazards model. Results: 46,350 women were identified for analysis. Taking stage, histology, race, and treatment into account, increasing age demonstrates negative prognostic significance with a HR of 2.87 for women over age 70 and 1.46 for women ages 50-69. Additionally, women over 70 are significantly more likely to receive non-aggressive treatment (<0.0001) or no treatment at all (p<0.0001). Of note, these women gain a significant survival advantage from treatment, even if less aggressive, as compared to no treatment (p<0.0001), with brachytherapy alone showing the greatest benefit (p<0.0001 vs NT; p<0.0087 vs EBRT) among less aggressive therapies. Brachytherapy continues to hold a significant survival advantage for all stages in women over 70 (localized: p=0.0009 vs. NT; regional and distant: p<0.0001 vs. NT). Older women with cervical cancer show a poor survival trend with risk analysis supporting that age is an independent negative prognostic factor when accounting for stage, histology, race, and treatment. They receive less aggressive treatment as compared to their younger counterparts, with a significant number receiving no treatment at all. Despite this, less aggressive therapy still extends survival, particularly with brachytherapy, supporting the immense potential clinical benefit. This study is novel in that it demonstrates that older women, who we show are at risk for a poorer prognosis because of their age, are not only receiving appropriate treatment less often, they are dying more frequently because of it. Our data supports that older women are a high-risk group of patients that would benefit significantly from treatment, even if only brachytherapy. Brachytherapy for cervical cancer is a tolerable procedure, even for most elderly women, and should, therefore, remain a standard clinical option for this population, regardless of their stage or histology at diagnosis.
Read full abstract